Sugi Predict

Sugi Predict / Compounds / SCHEMBL566498

SCHEMBL566498

SCHEMBL566498

CCOc1ccc(C(=O)O)cc1Cl

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 4/20 0.70
▸ MEN1 O00255 1/20 0.70
▸ LMNA P02545 1/20 0.70
▸ GAA P10253 1/20 0.70
▸ KMT2A Q03164 1/20 0.70
▸ MCL1 Q07820 1/20 0.70
▸ TDP1 Q9NUW8 1/20 0.70
▸ NPC1 O15118 4/20 0.69
▸ RAB9A P51151 4/20 0.69
▸ SMN1; SMN2 Q16637 4/20 0.69
▸ NFKB1 P19838 1/20 0.69
▸ NFKB2 Q00653 1/20 0.69
▸ RELA Q04206 1/20 0.69
▸ TSHR P16473 2/20 0.66
▸ MRGPRX4 Q96LA9 4/20 0.58
▸ MITF O75030 1/20 0.57
▸ MAPT P10636 2/20 0.56
▸ KDM4E B2RXH2 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.56
▸ NPSR1 Q6W5P4 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5347979 0.87 MEN1 (0.60) POLBMEN1LMNAGAAKMT2A
SCHEMBL177169 0.87 THRA (0.56) POLBMEN1LMNAGAAKMT2A
SCHEMBL1121665 0.86 TSHR (0.66) POLBMEN1LMNAGAAKMT2A
SCHEMBL11808755 0.86 POLB (0.58) POLBMEN1LMNAGAAKMT2A
SCHEMBL8204769 0.86 CREBBP (0.66) POLBMEN1LMNAGAAKMT2A
SCHEMBL337560 0.86 MRGPRX4 (0.58) POLBMEN1LMNAGAAKMT2A
SCHEMBL566466 0.85 THRA (0.66) POLBMEN1LMNAGAAKMT2A
SCHEMBL566426 0.85 THRA (0.62) POLBMEN1LMNAGAAKMT2A
SCHEMBL4464186 0.85 MAPK1 (0.67) POLBMEN1LMNAGAAKMT2A
SCHEMBL16954838 0.84 POLB (0.56) POLBMEN1LMNAGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024064024-A1 ((4-OXO-3,4-DIHYDROQUINAZOLIN-8-YL)METHYL)AMINE DERIVATIVES AS P13K INHIBITORS FOR THE TREATMENT OF CANCER ONKURE, INC. (US) 2024-03-28 — — WO disclosed
US-20220363640-A1 ANTIVIRAL COMPOUNDS Janssen Biopharma, Inc. (US) 2022-11-17 — — US disclosed
CN-114716426-A Antiviral compounds 詹森生物制药有限公司 2022-07-08 — — CN disclosed
CN-105636936-B Antiviral compounds 詹森生物制药有限公司 2022-04-05 — — CN disclosed
US-11021444-B2 Antiviral compounds Janssen Biopharma, Inc. (US) 2021-06-01 — — US disclosed
US-20190263754-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. (US) 2019-08-29 — — US disclosed
US-20180065932-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2018-03-08 — — US disclosed
EP-3036220-A1 ANTIVIRAL COMPOUNDS Alios Biopharma, Inc. (US) 2016-06-29 — — EP disclosed
US-9181182-B2 S1P receptors modulators AKAAL PHARMA PTY LTD (AU) 2015-11-10 — — US disclosed
US-20150065504-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. 2015-03-05 — — US disclosed
EP-0986559-A1 1,6-NAPHTHYRIDINE ANTI-CONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2000-03-22 — — EP disclosed
WO-2000009486-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSIVANTS SMITHKLINE BEECHAM P.L.C. (GB) 2000-02-24 — — WO disclosed
WO-2000008020-A2 TRICYCLIC CARBOXAMIDES SMITHKLINE BEECHAM P.L.C. (GB) 2000-02-17 — — WO disclosed
EP-0968190-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2000-01-05 — — EP disclosed
WO-1999065903-A1 TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY SMITHKLINE BEECHAM PLC (GB) 1999-12-23 — — WO disclosed
WO-1999031068-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1999-06-24 — — WO disclosed
WO-1999021836-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1999-05-06 — — WO disclosed
WO-1998054184-A1 1,6-NAPHTHYRIDINE ANTI-CONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1998-12-03 — — WO disclosed
WO-1998041508-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1998-09-24 — — WO disclosed
US-3936462-A CNS DEPRESSANT, ANALGESIC STERLING DRUG INC. (US) 1976-02-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190263754-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 POLB 429/4885MEN1 4812/4885LMNA 2978/4885
US-11021444-B2 Antiviral compounds MAVS, SARS1, ZC3HAV1 POLB 429/4885MEN1 4812/4885LMNA 2978/4885
US-20220363640-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 POLB 429/4885MEN1 4812/4885LMNA 2978/4885
US-20180065932-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 POLB 429/4885MEN1 4812/4885LMNA 2978/4885
US-20150065504-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 POLB 429/4885MEN1 4812/4885LMNA 2978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.